EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cumulative cefepime exposure in cancer patients is associated with an increased risk of ertapenem non-susceptible, meropenem susceptible Enterobacterales bacteremia

Alex V Stabler iD, William C Shropshire iD, Allyson Young, Chun Feng, Hyunsoo Hwang iD, Samuel A Shelburne iD, Nancy N Vuong, Jovan Borjan iD

Microbiology Spectrum · 07.04.2026 · 14 (4)

DOI: 10.1128/spectrum.02781-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 07.04.2026. Verfasst von Alex V Stabler und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Meropenem, Cefepime, Anti-Bacterial Agents, Enterobacteriaceae Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Carbapenem resistance in non-carbapenemase producing Enterobacterales can display susceptibility discordance (e.g., ertapenem-non-susceptible, meropenem-susceptible), often in patients with prior antimicrobial use. We aim to characterize risk factors for carbapenem susceptibility discordant Enterobacterales (CSD-E) bloodstream infections in immunocompromised patients. We performed a retrospective, single-center study comparing adults with Enterobacterales BSI who developed subsequent carbapenem susceptibility concordant (CSC; meropenem and ertapenem susceptible) or CSD-E BSI with the same organism within 1 year. Patients who developed subsequent CSD-E BSI were matched to those with repeat CSC-E BSI based on organism. Logistic regression models evaluated CSD-E risk factors. Time-varying covariate Cox proportional hazards models evaluated time-dependent changes in antibiotic exposure when estimating the association between antibiotic use and CSD-E. Comparative genomics of available paired whole-genome sequencing (WGS) data was performed to assess genetic relatedness and antimicrobial resistance (AMR) gene content. Beta-lactam survival mechanisms (BLSM) were assessed via Tolerance Disk Test (TDTest) and Population Analysis Profiling (PAP). We evaluated 829 patients with Enterobacterales BSI. Repeat BSI was CSC-E in 81 patients (9.8%) and CSD-E in 14 patients (1.7%). Matching provided 43 CSC-E controls and 14 CSD-E cases. Univariate analysis revealed any ceftazidime-avibactam (CZA) exposure was associated with developing CSD-E BSI (odds ratio [OR], 7.41; P = 0.01). Time-varying covariate Cox regression identified each additional day of cefepime is associated with CSD-E BSI development (hazard ratio [HR], 1.055; P = 0.016). Genomic data suggest beta-lactamase amplification and outer membrane porin mutations may be potential CSD-E development mechanisms. CSD-E BSI risk factors in immunocompromised patients may include any CZA exposure and cumulative cefepime exposure. Further studies are warranted to validate CSD-E risk factors. IMPORTANCE Non-carbapenemase-producing (non-CP) carbapenem-resistant Enterobacterales (CRE) are an important classification of CRE. Increasing rates of non-CP CRE that display carbapenem susceptibility discordance (CSD-E; ertapenem-resistant, meropenem susceptible) have been observed globally and at our institution. Our article aims to characterize risk factors, including cumulative antibiotic exposure, leading to carbapenem susceptibility discordant Enterobacterales (CSD-E) bloodstream infection (BSI) in immunocompromised patients with a history of Enterobacterales BSI. In addition, we analyzed paired whole-genome sequencing data to assess antimicrobial gene content for mechanistic rationales supporting our clinical findings. The risk factors for CSD-E development identified in this study require further validation in multicenter cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeropenemCefepimeAnti-Bacterial AgentsEnterobacteriaceae InfectionsErtapenemBacteremiaNeoplasmsEnterobacteriaceaeHumansRetrospective StudiesFemaleMaleMicrobial Sensitivity TestsThird Generation CephalosporinsMiddle AgedAgedbeta-LactamasesRisk FactorsCarbapenemsCeftazidime

Stichwörter der Autor:innen

Enterobacteralesbloodstream infectioncarbapenem discordant

Substanzen

MeropenemCefepimeAnti-Bacterial AgentsErtapenemThird Generation Cephalosporinsbeta-LactamasesCarbapenemsCeftazidime

Autor:innen und Institutionen

  • Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Pharmacy Quality-Regulatory, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Alex V Stabler, William C Shropshire, Hyunsoo Hwang, Samuel A Shelburne, Jovan Borjan

Zitieren

APA

Stabler, A. V., Shropshire, W. C., Young, A., Feng, C., Hwang, H., Shelburne, S. A., Vuong, N. N., & Borjan, J. (2026). Cumulative cefepime exposure in cancer patients is associated with an increased risk of ertapenem non-susceptible, meropenem susceptible Enterobacterales bacteremia. Microbiology Spectrum, 14(4). https://doi.org/10.1128/spectrum.02781-25

Vancouver

Stabler AV, Shropshire WC, Young A, Feng C, Hwang H, Shelburne SA, et al. Cumulative cefepime exposure in cancer patients is associated with an increased risk of ertapenem non-susceptible, meropenem susceptible Enterobacterales bacteremia. Microbiology Spectrum. 2026;14(4). doi:10.1128/spectrum.02781-25

BibTeX
@article{Stabler2026,
  author = {Stabler, Alex V and Shropshire, William C and Young, Allyson and Feng, Chun and Hwang, Hyunsoo and Shelburne, Samuel A and Vuong, Nancy N and Borjan, Jovan},
  title = {Cumulative cefepime exposure in cancer patients is associated with an increased risk of ertapenem non-susceptible, meropenem susceptible Enterobacterales bacteremia},
  journal = {Microbiology Spectrum},
  year = {2026},
  volume = {14},
  number = {4},
  doi = {10.1128/spectrum.02781-25}
}
Kostenlos starten →